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license (http://creativeHowever, the dose-dependent impact of this allele on brain morphology of healthy individuals
remains unclear.
Methods: We analyzed gray matter volumes (GMvs) in a sample of 533 healthy middle-aged
individuals with a substantial representation of ε4-carriers (207 heterozygotes and 65 homozygotes).
Results: We found APOE-ε4 additive GMv reductions in the right hippocampus, caudate, precentral
gyrus, and cerebellar crus. In these regions, the APOE genotype interacted with age, with
homozygotes displaying lower GMv after the fifth decade of life. APOE-ε4 was also associated to
greater GMv in the right thalamus, left occipital gyrus, and right frontal cortex.
Discussion: Our data indicate that APOE-ε4 exerts additive effects on GMv in regions relevant for
Alzheimer’s disease pathophysiology already in healthy individuals. These findings elucidate the
mechanisms underlying the increased Alzheimer’s disease risk in ε4-carriers, suggesting a
dose-dependent disease vulnerability on the brain structure level.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; APOE-ε4; Healthy individuals; Voxel-based morphometry; Gray matter volumes; Agingd scientific advice or has been an investigator or data
ber receiving consultancy fees from Novartis, Pfizer,
Lundbeck, Roche, Bayer, Bristol-Myers Squibb, GE
SD, GlaxoSmithKline, Astra-Zeneca, Avid, Lilly,
n, Biokit, Piramal, IBL, and Fujireibio-Europe.
R.C., C.F, A.B., G.S.-B, N.G., S.M., M.E., C.M., K.F., and J.D.G. reported
no biomedical financial interests or potential conflicts of interest.
*Corresponding authors. Tel.: 134 933160990; Fax: 134 932275783.
E-mail address: jlmolinuevo@fpmaragall.org (J.L.M.), jdgispert@
fpmaragall.org (J.D.G.)
/j.jalz.2018.01.016
he Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND
commons.org/licenses/by-nc-nd/4.0/).
R. Cacciaglia et al. / Alzheimer’s & Dementia 14 (2018) 902-912 9031. Background
Alzheimer’s disease (AD) is an irreversible neuro-
degenerative disorder characterized by progressive cognitive
impairment and a characteristic pattern of regional brain
atrophy that starts in the hippocampus and medial temporal
regions and then spreads to other cortical areas [1]. The two
major neuropathologic features of AD are extracellular
fibrillary amyloid b (Ab) plaques and intracellular
neurofibrillary tau tangles. AD pathology develops slowly
with a protracted preclinical phase characterized by
abnormal cerebral Ab deposition in cognitively intact
individuals [2]. The apolipoprotein E (APOE)-ε4 represents
the major genetic risk factor for late-onset AD, with
increasing copies of the ε4 allele being associated to greater
AD risk and younger age of disease onset [3,4]. Three
common polymorphic alleles referred as ε2, ε3, and ε4
code, respectively, three distinct apoeE isoforms, which
differ among each other by a single amino acid, and
depending on the allele pairs, they result in six possible
diploid haplotypes. In the brain, apoE mediates neuronal
delivery of cholesterol, which is an essential component
for axonal growth, synaptic formation, and remodeling,
and has an important role in Ab metabolism. The apoE4
isoform (coded by the APOE-ε4 allele) has been shown to
be less efficient in Ab clearance and cholesterol transport
than the other isoforms (apoE2 . apoE3 . apoE4) [4].
APOE-ε4-homozygous (HO) individuals are therefore an
interesting population for studying the long-term effects of
the lack of expression of the more efficient apoE isoform.
Regarding the pathogenesis of AD, the mechanisms through
which APOE-ε4 increases risk can be regarded as conferring
a loss of neuroprotective function, gain of neurotoxic
function, or both [4]. APOE-ε4 allele dose effects on
memory decline have been reported in cognitively healthy
individuals [5], and a dose-dependent hippocampal gray
matter (GM) degeneration has been observed in AD patients
[6,7]. However, only a few reports have assessed the impact
of APOE-ε4 homozygosity on the brain morphology of
healthy middle-aged subjects. One cross-sectional study
found significantly reduced hippocampal volume in healthy
APOE-ε4 homozygotes, as compared to ε4-heterozygotes
and noncarriers (NC), without however reporting any ε4
dose-dependent effects [8]. In the follow-up of this study,
an age-related hippocampal volume loss was found only in
homozygotes, again not supporting for APOE-ε4 additive
effects in this region [9]. On the other hand, Chen et al.
[10] reported a significant correlation between APOE-ε4
gene dose and higher annualized rates of whole-brain
atrophy in healthy individuals.
Aside from these reports, most of the studies in the
literature pooled together APOE-ε4 homozygotes and
heterozygotes into a single APOE-ε4 carrier category.
Although longitudinal studies reported significantly faster
decays of regional gray matter volume (GMv) in healthy
carriers compared to NC [11,12], most cross-sectionalstudies which determined volumes in a priori–defined
AD-sensitive cerebral regions did not find significant group
differences [13–15]. Similarly, null findings were reported in
studies using voxelwise techniques, such as voxel-based
morphometry (VBM) [16–18]. By contrast, two studies
using VBM reported GMv differences in brain regions
including the hippocampus, lingual gyrus, and precuneus,
when comparing carriers to NC [19,20]. More recently,
Ten Kate et al. [21] reported decreased volume in the
precuneus and insula in healthy middle-aged carriers of
the risk allele as well as an interaction between APOE status
and age in determining GMv in temporal and occipital
regions. Discrepancies among studies might be in part due
to the volumetric technique adopted and the difference in
the samples’ age, where studies including relatively older
individuals tend to report significant differences compared
to those including younger samples.
In the present study, we sought to determine the effects of
APOE-ε4 allele load on brain morphology to better
characterize the mechanisms through which APOE-ε4
confers an increased risk to develop AD in the healthy
population. To this end, we used VBM in a cohort of healthy
middle-aged individuals enriched for this genetic risk for
AD (261 NC, 207 APOE-ε4 heterozygotes, and 65 APOE-ε4
homozygotes). We also sought to determine potential
interactions between APOE status and age in determining
GMv variability.2. Methods
2.1. Study participants
The recruitment for the study consisted of two steps.
First, 2743 cognitively healthy volunteers aged between 45
and 76 years were enrolled in the ALFA (ALzheimer and
FAmilies) study, a large cohort program pointing to the
identification of neuroimaging biomarkers of preclinical
AD in the general population [22]. Exclusion criteria
included performance exceeding established cutoff for a
number of cognitive tests and presence of a psychiatric
diagnosis [22]. Second, after APOE genotyping, all
participants homozygous for the ε4 allele as well as carriers
of the ε2 allele were invited to undergo magnetic resonance
imaging (MRI) scanning along with ε4-heterozygous (HE)
and NC matched for age and sex. This sampling strategy
resulted in 576 study participants, of which 43 had to be
discarded due to either MRI incidental findings or poor
image quality, resulting in the final sample included in our
study of 533 individuals. Demographic characteristics
of the participants are summarized in Table 1 and
Supplementary Table 1. For the statistical analyses,
participants were pooled according to the cumulative
presence of the ε4 allele, that is, NC, HE, and HO. Total
intracranial volume as well as gender and education years
did not differ among the three groups. However, HO
individuals were significantly younger than NC and HE
Table 1
Sample characteristics
Total sample (N5 533) NC (N 5 261) HE (N 5 207) HO (N 5 65)
Inferential statisticsM SD M SD M SD M SD
Age* 57.58 7.43 57.93 7.53 58.22 7.41 54.14 6.18 F 5 8.22; P , .01
Education* 13.64 3.56 13.69 3.62 13.66 3.53 13.38 3.46 F 5 0.19; P 5 .82
TIV (cm3) 1490.11 146.07 1484.96 155.17 1495.41 137.73 1493.91 135.20 F 5 0.32; P 5 .72
Male/female 213/320 95/166 94/113 24/41 c2 5 4.19; P 5 .13
Abbreviations: NC, noncarriers; HE, ε4-heterozygous; HO, ε4-homozygous; M, mean; SD, standard deviation; TIV, total intracranial volume.
*Indicated in years.
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all subsequent analyses. The study was approved by the local
ethics committee, and all participants gave written informed
consent to participate in the study.2.2. APOE genotyping
Total DNAwas obtained from the blood cellular fraction
by proteinase K digestion followed by alcohol precipitation.
Samples were genotyped for two single-nucleotide
polymorphisms, rs429358 and rs7412, determining the
possible APOE isoforms: ε1, rs429358 (C) 1 rs7412 (T);
ε2, rs429358 (T) 1 rs7412 (T); ε3, rs429358
(T) 1 rs7412 (C); and ε4, rs429358 (C) 1 rs7412 (C). Of
the 533 participants, 163 were ε3/ε4 carriers, 149 were
homozygous for the ε3 allele, 105 were ε2/ε3 carriers,
65 were homozygous for the ε4 allele, 44 were ε2/ε4, and
7 were ε2/ε2 carriers. The allele frequencies were in
Hardy-Weinberg equilibrium.2.3. Image data acquisition and preprocessing
MRI was conducted with a 3T General Electric scanner
(GE Discovery MR750 W). Structural 3D high-resolution
T1-weighted images were collected using a fast spoiled
gradient-echo sequence implementing the following
parameters: voxel size 5 1 mm3 isotropic, repetition
time 5 6.16 ms, echo time 5 2.33 ms, inversion
time 5 450 ms, matrix size 5 256 ! 256 ! 174, and flip
angle 5 12. Images were segmented into GM tissue using
the new segment function implemented in Statistical
Parametric Mapping software (SPM12; Wellcome
Department of Imaging Neuroscience, London, UK) and
located into a common space for subsequent normalization
using a 9-affine parameter transformation. GM images
were then used to generate a reference template object of
the sample, which was warped into a standard Montreal
Neurological Institute space using the high-dimensional
DARTEL toolbox [23]. The generated flow fields and
normalization parameters were then implemented to
normalize the native GM T1 images to the Montreal
Neurological Institute space. Jacobian determinants were
applied to preserve the local native amount of GM
(modulated images). Quality control of normalization wasassured by checking the sample homogeneity with the
computational anatomy toolbox (CAT12) (http://dbm.
neuro.uni-jena.de/cat/) using non-smoothed data, which
did not return errors in the registration procedure in any
subject. Finally, images were spatially smoothed with a
6-mm full width at half maximum gaussian kernel. Total
intracranial volume was computed by summing the
segmented GM, white matter, and cerebrospinal fluid for
each individual.2.4. Neuropsychological assessment
Global cognition was assessed using the Mini–Mental
State Examination (MMSE) [24], whereas episodic memory
was assessed with the Memory Binding Test [25], and
executive functions were evaluated using theWechsler Adult
Intelligence Scale [26]. We computed a global score of
immediate recall by summing up all individual scores
from the total paired recall and total free recall scales of
the Memory Binding Test. Similarly, a global index of
delayed recall was obtained by summing scores of total
delayed paired recall and total delayed free recall.2.5. Statistical analyses
The normalized, modulated, and smoothed GM images
were entered in a multiple regression design in SPM12.
We partitioned genetic variance by including in the design
matrix two independent dummy regressors coding both
additive and other genotypic effects of APOE-ε4, as
proposed for analyzing quantitative trait loci [27,28] and
as previously implemented in neuroimaging studies [7].
Briefly, a genetic additive model predicts an incremental
response of the quantitative trait according to the allelic
load, whereas a dominant model predicts a common
response to 1 or 2 copies of the risk allele. Finally, a
recessive model predicts a common response to 0 or 1
copy of the risk allele. Linear and quadratic expansions of
age, as well as sex, years of education, and total intracranial
volume, were included as covariates. To control for
multicollinearity, age and age squared were centered at their
respective mean. Because previous studies reported
significant interactions between APOE status and age in
determining GMv variability [21], we fitted the model
Table 2
Significant GMv differences between APOE-ε4 carriers and noncarriers for the hypothesis-driven and whole-brain analyses





Right hippocampus 25.11 137 ,.001 .003 21 236 8
Right thalamus 4.67 192 ,.001 .02 12 212 6
Additive model
Right hippocampus 24.91 154 ,.001 .008 21 236 8
Right thalamus 4.47 214 ,.001 .04 12 212 6
Whole-brain analysis
Genotypic model
Right hippocampus 25.11 194 ,.001 .01 21 236 8
Right cerebellar crus 24.14 102 ,.001 .37 53 253 244
Right caudate 23.70 157 ,.001 .88 11 14 11
Right thalamus 4.67 193 ,.001 .06 12 212 6
Left middle occipital 4.33 248 ,.001 .21 219 296 9
Right superior frontal 3.75 122 ,.001 .84 23 48 21
Additive model
Right hippocampus 24.91 209 ,.001 .02 21 236 8
Right cerebellar crus 23.93 101 ,.001 .64 51 253 244
Right precentral 23.85 117 ,.001 .73 45 26 59
Right caudate 23.69 102 ,.001 .88 11 20 8
Right thalamus 4.42 202 ,.001 .16 12 212 6
Left middle occipital 4.19 208 ,.001 .33 219 296 9
Abbreviations: APOE, apolipoprotein E; GMv, gray matter volume;MNI,Montreal Neurological Institute; PFWE, P value corrected for multiple comparisons
using a family-wise error rate approach.
*Negative t-values indicate APOE-ε4-related GMv reductions, whereas negative values indicate opposite effects.
yCluster size indicated in number of contiguous voxels.
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squared. Additive and genotypic effects of APOE-ε4 on
GM volumes were separately assessed with t-test contrasts
on the respective regressors. Potential interactions between
APOE status and agewere assessed with t-tests implemented
on both linear and quadratic interaction terms in the design
matrix. To disentangle the specific contribution of each
APOE haplotype in determining GMv group differences,
we performed a separate model where five orthogonal
dummy regressors were entered as independent predictors.
Because the number of individuals homozygous for the
ε2 allele was only seven, we collapsed this group with the
ε2/ε3 genotype group yielding a single category that we
coded as ε2/ε2 1 ε2/ε3.
First, we performed a hypothesis-driven analysis that was
restricted to all voxels within an a priori–defined anatomical
region of interest (ROI) that included cerebral areas
specifically affected by AD, as recently reviewed by
Chapleau et al. from previous VBM studies [1]. This mask
included the following bilateral regions: hippocampus,
thalamus, precuneus, posterior cingulum, angular gyrus,
inferior and middle temporal gyri, superior temporal pole,
middle occipital cortex, insula, fusiform gyrus, and the
straight rectus. For this analysis, we performed a small
volume correction as implemented in SPM12, selecting a
primary voxelwise threshold of uncorrected P , .001 and
successively applying a correction for multiple testing usinga family-wise error rate (FWE) approach [29]. Second, we
performed an unbiased whole-brain analysis to detect
additional effects of APOE-ε4 in our genetically enriched
sample. For this exploratory analysis, results were
considered significant if surviving a voxelwise statistical
threshold of uncorrected P , .001, with a cluster-extent
threshold of 100 voxels. This cutoff is reliably conservative
and further protects against type I error [30,31]. The effect
size of the APOE-ε4 load on GMv was computed
voxelwise by converting F-maps into equivalent
correlational effects (r-values). All cognitive measures
were entered in a univariate analysis of variance with the
independent factor being the number of ε4 alleles
(3 levels) and additionally controlling for age, sex, and
years of education. For visualization of the statistical
parametric maps, we used xjView (http://www.alivelearn.
net/xjview).3. Results
3.1. Main effect of APOE genotype
When assessing genotypic effects, the ROI analysis
returned significant results in the right posterior
hippocampus and right medial thalamus. Specifically,
compared to NC, ε4-carriers demonstrated a lower GMv in
the right posterior hippocampus while showing greater
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were also significant when assessing ε4 allele additive ef-
fects, indicating that ε4-carriers showed reduced posterior
right hippocampal and increased right thalamic volume in
a dose-dependent manner (Table 2).
The exploratory whole-brain analysis confirmed the
significantly additive reduced GMv in carriers compared to
NC in the right posterior hippocampus and additionally
revealed significant ε4 additive effects in the same direction
in the right caudate nucleus, right precentral gyrus, and right
cerebellar crus (Table2; Fig. 1A, 1B, and 1D). The right
hippocampus survived FWE correction also in this unbiased
analysis (PFWE 5 0.023). In addition, the whole-brain
analysis confirmed the dose-dependent hypertrophy in
carriers compared to NC in the right medial thalamus and
also yielded an additive effect of APOE-ε4 in the left middle
occipital gyrus as well as a genotypic effect in the same
direction for the right superior frontal cortex (Table 2;
Fig. 1A, 1C, and 1E). Removing the ε2/ε4 carriers from
the analysis did not significantly alter the results.
Supplementary Fig. 1 shows the effects size of the additive
and genotypic effects of APOE-ε4 allele load across the
whole brain, which were relatively small to moderate and
displayed a symmetric pattern. Supplementary Table 2 sum-
marizes GMv difference among the five APOE genotype
groups, as revealed by planned t-test comparisons. Presence
of the APOE-ε4 was not significantly associated to cognitive
performance in any of the analyzed cognitive domain
(Supplementary Table 3). Furthermore, we observed no sig-
nificant difference in cognitive performance among each of
the five APOE genotype groups (Supplementary Table 4).
To better investigate whether APOE-ε4-allelic load
modulates the association between GMv and cognitive
performance, we performed a post hoc analysis by modeling
the interaction between APOE status and scores of episodic
memory as well as executive function. In so doing, we
performed an ROI analysis in SPM using an anatomical
mask, which included the clusters where we observed the
main effects of APOE-ε4 described previously. Given the
exploratory nature of this post hoc ROI analysis, we
selected a voxelwise primary threshold of P , .05.
We observed a significant interaction between APOE
status and executive function performance, specifically
the HO individuals were the only group displaying a
negative association between GMv in the caudate as
well as the cerebellar crus and scores in two subscales
of the Wechsler Adult Intelligence Scale (Digit-
Symbol Substitution Test and Digit-Span Sequencing;
Supplementary Fig. 2). No significant interactions were
observed in the selected ROIs between APOE status and
episodic memory.3.2. Interaction between APOE genotype and age
When assessing genotypic effects, the hypothesis-driven
analysis returned a significant interaction between APOEgenotype and age in the right posterior hippocampus
(t521 5 24.82, cluster size [k] 5 234, PFWE 5 .01). The
whole-brain analysis assessing genotypic effects confirmed
the significant interaction in the right posterior
hippocampus, which also survived FWE correction
(PFWE 5 .034), and additionally revealed an interaction in
the right caudate (t521 5 23.80, k 5 198, P , .001), as
well as the right (t521 5 25.53, k 5 268, P , .001) and
left (t521 5 24.06, k 5 157, P , .001) cerebellar crus
(Fig. 2A and 2B). The interaction effects in all these four
regions were also significant when assessing ε4 additive
effects (P , .001, k . 100), indicating an APOE-ε4
dose-related regional GMv reduction over age in our
cross-sectional design. The effect size for the interaction
between APOE status and age was small to moderate and
showed symmetric pattern resembling that of the main
effects (Supplementary Fig. 1).4. Discussion
We have reported that the APOE-ε4 genotype
significantly impacts on GMv in a group of 533 healthy
middle-aged individuals. We capitalized on a cohort
harboring a significantly higher number of APOE-ε4
homozygotes than previously reported in single-site studies
of healthy subjects. This allowed us to reliably assess the
effects of the risk allele on gray matter morphology. We
observed a highly symmetrical morphological pattern, of a
small-to-moderate effect size, associated to the additive
effects of APOE-ε4 load across the whole brain, although
these effects were mainly driven by the homozygous group
(Figs. 1 and S1).
We found a main effect of APOE-ε4 in determining GMv
reduction of the posterior hippocampus, in a dose-dependent
fashion. In this region, we also observed a significant
interaction with age, where the HO group displayed a
departure of hippocampal GMv after the fifth decade of
life, with respect to both NC and HE. Our interaction
findings resemble previous data reported by Caselli et al.
[5] who found a significant linear relationship between the
ε4-allelic load and the age-related memory decline in
cognitively intact individuals and may in fact represent a
brain structural correlate of those results. However, we did
not find a significant impact of the APOE-ε4 risk variant
on cognitive performance. Such a null finding matches
previous works documenting moderate if not null effects
of the ε4 allele on cognitive performance in healthy
middle-aged individuals when examined cross-sectionally
[32,33]. Hippocampal degeneration is the most typical
characteristic of AD, where hippocampal atrophy rates
positively correlate with the APOE-ε4 allele load [34]. In
addition, a lower hippocampal volume in nondemented
individuals has been reported to increase the risk of
developing AD [35,36] and to be associated to higher
cerebrospinal fluid tau levels [37]. In particular, the posterior
hippocampus is among the first regions suffering structural
Fig. 1. APOE-ε4 genotype impacts on GMv in healthy middle-aged individuals. (A) Statistical parametric maps showing the brain regions where the APOE-ε4
allele had a significant impact on GMv. For visualization purposes, the maps are thresholded at P, .005 uncorrected for multiple testing. Green-colored areas
indicate additive effects of the risk allele in determining GMv reductions, whereas red-colored areas indicate opposite effects. In the whole brain, we observed a
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Fig. 2. Significant interactions between APOE genotype and age in determining regional GMv variability in healthy individuals. (A) APOE-ε4 carriership
significantly interacted with age in four brain regions, determining distinct age-related trajectories of GMv depending on the number of the risk alleles.
Significant interactions were found in the right hippocampus, right caudate nucleus, and in the right and left cerebellar crus. In these regions, APOE-ε4 was
related to steeper nonlinear decline of GMv across age, with homozygous showing the greatest effect. The age-related GMv trajectories diverged among groups
between the fifth and sixth decades of life. For visualization purposes, nonparametric smoothing spline functions were used to fit the data. Shaded gray areas
indicate 90% confidence intervals. (B) Same as in (A), with the APOE genotype groups broken down into five categories. Abbreviations: APOE, apolipoprotein
E; GMv, gray matter volume.
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undergoes GMv loss in AD but not in other types of
dementias [1]. In fact, HO individuals present a significantly
younger mean age of onset of AD (68 years) [3,4]. Together
with our findings, this would suggest that the older APOE-ε4
homozygotes in our sample might have already started the
neurodegenerative process, although with cognition still
within normal ranges. However, other effects of the
APOE-ε4 allele that may precede or be independent ofhighly symmetrical pattern of effects exerted by the APOE-ε4 genotype. (B) Mean
risk allele survived statistical threshold, determining lower APOE-ε4 dose-depe
adjusted GMv in the regions where the effect of the risk allele survived statistica
the superior frontal cortex where the effects were recessive with the ε4 allele. E
in the regions reported in (B), across five different APOE haplotypes. Error bar
regions reported in (C), across five different APOE haplotypes. Error bars ind
HE, ε4-heterozygous; HO, ε4-homozygous; SEM, standard error of the mean.
=
amyloid deposition have been described in the literature,
such as impaired cholesterol delivery to the brain to
sustain synaptic integrity and plasticity, promotion of
proinflammatory responses or to maintain vascular health
[4]. Therefore, an alternative explanation to our finding
would be that the ε4 allele load renders the brain tissue
more vulnerable to insults inherently provoked by
aging, but not necessarily associated to AD pathology.
Longitudinal multimodal studies with the acquisition of-centered bar plots of the adjusted GMv in the regions where the effect of the
ndent GMv. Error bars indicate SEM. (C) Mean-centered bar plots of the
l threshold, determining higher APOE-ε4 dose-dependent GMv, except for
rror bars indicate SEM. (D) Mean-centered bar plots of the adjusted GMv
s indicate SEM. (E) Mean-centered bar plots of the adjusted GMv in the
icate SEM. Abbreviations: GMv, gray matter volume; NC, noncarriers;
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the contribution of APOE-ε4 to these distinct biological
mechanisms.
Previous cross-sectional structural MRI studies
conducted in healthy individuals found discordant results
on the relationship between APOE-ε4 and hippocampal
volume [38]. Former cross-sectional [8] and longitudinal
studies [9] conducted in healthy individuals concluded that
no ε4 gene dose effects were present in the hippocampal
volume or their change rates. Nonetheless, although we
found significant effects when testing the additive model,
we should again emphasize that our data were mainly driven
by the APOE-ε4 group; therefore our data are partially in
agreement with the previously cited studies. Our
finding on the dose-dependent GMv reduction in the
posterior hippocampus may represent one mechanism for
the dose-dependent AD vulnerability exerted by APOE-ε4
[3,4].
The whole-brain analysis detected additional ε4
additive GMv reductions in three regions: the right caudate
nucleus, the right cerebellar crus, and the right precentral
gyrus.
Of these regions, the former two also displayed an
interaction with age in a similar direction as for the posterior
hippocampus, whereas the latter did not. Two previous
studies reported caudate atrophy in healthy APOE-ε4
carriers [21,39]. In addition, the caudate and the crus of
the cerebellum, together with other cortical areas, form
part of the extended network subserving executive
functions [40], and the volume of the cerebellar crus is
specifically related to efficiency in multiple cognitive
domains including executive functioning [41]. Of interest,
this executive control network has been reported to be
selectively affected in AD [42]. To test whether the
APOE-ε4-allelic load would modulate the association
between volumes in these regions and cognitive
performance, we performed a post hoc analysis. We looked
for the associations between GMv in these regions and
executive function and sought for an interaction effect
with APOE-ε4 allele load. We found significant interactions
for the Digit-Symbol Substitution Test and Digit-Span
Sequencing subscales of the Wechsler Adult Intelligence
Scale in the caudate and cerebellar crus. In these areas, lower
executive performance was associated to increased GMv in
the ε4 homozygote group only, although no between-group
differences were detected in executive function. On the other
hand, no interactions were observed for episodic memory
measurements. This effect may indicate that GMv changes
in these areas could be related to the decline in executive
function reported in preclinical AD stages [43]. However,
to confirm this hypothesis, the impact of APOE-ε4 load on
the neuroanatomical correlates of cognition calls for
additional investigations and further studies shall address
this on a brain connectivity network level, something which
goes beyond the scope of the present article. Anotherpossible interpretation would be that other effects of the
APOE-ε4 allele that may precede or be independent of
amyloid deposition impact executive function. In this
respect, APOE-ε4 has been linked to impaired cholesterol
delivery to the brain to sustain synaptic integrity and
plasticity. Therefore, to discern whether the impact of
APOE-ε4 load on the neuroanatomical correlates of
cognition in healthy subjects is independent of the presence
of neuropathological abnormalities, further studies with core
AD biomarkers are needed. Our finding on the additive
effect of APOE-ε4 in determining lower volume in the
precentral gyrus is in line with another study reporting
thinner sensorimotor cortex in children and adolescent
carriers of the ε4 allele [44], although these regions are
structurally affected only in the later stages of AD. The
lack of interaction in our findings with age in the precentral
gyrus suggests that this effect represents a genetically
determined neuroanatomical trait rather than being
associated to AD pathology. Nevertheless, the main effect
in the study of Shaw et al. [44] was located in the
entorhinal region, a brain region where we did not observe
APOE-ε4-related alterations. A different longitudinal
evolution with aging or the impact of early AD-related
pathological events in this area could underlie such null
finding.
Our hypothesis-driven analysis yielded a significant
APOE-ε4 dose-dependent additive GMv increase in the right
medial thalamus. This result was confirmed in the
whole-brain analysis, which additionally revealed a
dose-dependent GMv increase in the left middle occipital
cortex and a genotypic (recessive with the ε4 allele) GMv
increase in the right superior frontal cortex. The hypertrophy
we detected in the superior frontal cluster is in line with
one study reporting greater GMv in this area in healthy
ε4-carriers compared to NC [21]. Our data are also
consistent with two prior studies conducted in healthy
subjects having a similar age range as our sample, which
showed thicker frontal and occipital areas in APOE-ε4
carriers compared to NC [45,46]. Increased regional GMv
in temporal areas has been previously described in
amyloid-positive healthy individuals [47] who were
hypothesized to reflect brain swelling associated to glial
activation in preclinical AD stages [48]. However, given
the lack of pathological and neuroinflammatory markers,
we could not confirm this interpretation. Similarly, Johnson
et al. [49] found greater GMv in the lateral parietal and right
ventral temporal lobes in amyloid-positive cognitively
healthy subjects. In individuals with intermediate amyloid
levels, they also found increased fludeoxyglucose uptake
in the thalamus. Additional multimodal longitudinal studies
are needed to elucidate the temporal evolution of these
neuroimaging correlates. The effect of APOE-ε4 on cerebral
Ab deposition in cognitively healthy individuals has been
found to be dose-dependent and increased in homozygotes
in extensive brain areas including the basal ganglia, as
R. Cacciaglia et al. / Alzheimer’s & Dementia 14 (2018) 902-912910well as frontal and occipital cortices [50]. In fact, at the mean
age in our sample, about 50% of ε4 homozygotes are ex-
pected to harbor Ab pathology while only 20% of the hetero-
zygotes and ,10% of the NC [51]. Therefore, our findings
might represent an early event in the AD cascade in reaction
to the presence of aggregated Ab, in a process that eventu-
ally leads to GM atrophy, as already proposed earlier
[30,49]. However, we did not observe a significant
interaction with age in any of the brain regions where
APOE-ε4 was associated to greater GMv, as would have
been expected should these increments be associated with
amyloid deposition. This could be explained by a lower
effect size of inflammatory effects in brain structure as
compared to neurodegeneration. Certainly, other possible
APOE-related biological mechanisms other than Ab
aggregation could underlie our findings, such as defective
neuronal pruning [52], initial compensatory response to
neuronal stress, and progressive age-related loss of
compensation [53,54] or broader processes related to
accelerated aging [46]. Other explanations would include a
selection bias in our sample. APOE-ε4 homozygotes are
less likely to remain cognitively intact after the age of 60
years. Therefore, the inclusion criteria in our study could
have favored the inclusion of older APOE-ε4 homozygotes
with a higher cognitive or brain reserve, potentially driving
our results.
On the other hand, we did not observe any effects in areas
known to display reduced glucose metabolism in a
dose-dependent manner with APOE-ε4 allele load, such as
the precuneus, posterior cingulate, and parietotemporal
areas, also known to be affected in AD [55]. This is in
agreement with previous reports that studied the linkage
between fludeoxyglucose positron emission tomography
and GMvs in which the latter did not reach statistical
significance independently [56].
When inspecting the contribution of five different
haplotypes, our interaction data suggest that the group
ε2/ε2 1 ε2/ε3 displays relatively spared lifetime regional
GMv values. Although our study is cross sectional, this
suggests that these two haplotypes may be related to healthy
aging and longevity. The assessment of this aspect goes
beyond the scope of the present research and should be
investigated in future prospective studies. When modeling
the effects of each APOE haplotype on regional GMv, we
found a pattern of results that confirmed the ε4
dose-dependent effects in all regions except the right
superior frontal gyrus, as discussed previously. In addition,
this analysis revealed that the greatest difference in regional
GMv occurred between the ε2/ε2 1 ε2/ε3 and ε4/ε4
genotype groups.
When considering the present study, one should be
aware of the cross-sectional nature of our design, which
makes difficult to interpret the results in terms of temporal
evolution of the events because data were collected in a
single time point. Although this represents a limitation
of our study, it also encourages the development of morecomprehensive longitudinal studies to be conducted in
the healthy population, which shall address more
specifically the relationships between APOE-ε4 load and
aging in determining structural brain changes. Another
limitation of our study is the lack of core AD (i.e., Ab
and tau) or other inflammatory biomarkers. Although our
morphometrical data help to uncover the plausible
mechanisms that relate APOE genotype and AD
pathogenesis, we cannot clearly establish the biological
processes underlying our findings in GMvs without
specific biomarker data. Future studies shall take these
parameters into consideration.
As a possible methodological development of our
research, future studies shall consider the implementation
of multivariate statistical approaches, which may reveal
patterns of structural GM covariance and already proved
insightful for the assessment of the age-related structural
brain correlates [57].
Another important aspect is that our sampling strategy
was designed to maximize the number of APOE-ε4
homozygotes. Therefore, the allele frequencies in our study
are not representative of those of an unselected population,
which prevents us from drawing any epidemiological
conclusions.
In summary, we report region-specific additive and
recessive main effects of the APOE-ε4 on GMvs in healthy
individuals as well as interactions between APOE status
and age in determining GMvs in these areas. Our data
mirror previous findings of the ε4 additive effects on
cortical degeneration in AD patients and suggest that the
dose-dependent risk for AD conferred by APOE-ε4
may be reflected by altered GMvs already in healthy
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1. Systematic review: Apolipoprotein E (APOE)-ε4
confers dose-dependent increased risk for
Alzheimer’s disease (AD). In AD patients, APOE-
ε4 exerts additive effects in determining the degree
of hippocampal atrophy. However, only a few reports
have assessed dose-dependent effects of the risk
allele on brain morphology in healthy individuals
at higher risk of AD.
2. Interpretation: We found additive effects of APOE-
ε4 determining lower gray matter volume in the right
hippocampus, caudate, precentral gyrus, and cere-
bellar crus. APOE-ε4 was also associated to greater
gray matter volume in the right thalamus, left occip-
ital gyrus, and right frontal cortex. Our data suggest
that the dose-dependent vulnerability induced by
APOE-ε4 may be reflected on the brain morpholog-
ical level in regions that are critical for AD patho-
physiology.
3. Future directions: Future studies shall take into ac-
count AD biomarkers such as Ab or tau protein to
better characterize the underlying biological mecha-
nisms through which APOE-ε4-allelic load predis-
poses individuals to AD.References
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